How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bucy-vs-buflu.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

BuCy vs BuFlu — Competitive Intelligence Brief

BuCy vs BuFlu (BuCy vs BuFlu) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy conditioning regimen. Area: Oncology / Hematology.

phase 3 Chemotherapy conditioning regimen Oncology / Hematology Small molecule Live · refreshed every 30 min

Target snapshot

BuCy vs BuFlu (BuCy vs BuFlu) — Cooperative Study Group A for Hematology. BuCy and BuFlu are conditioning regimens that use chemotherapy agents (busulfan combined with either cyclophosphamide or fludarabine) to prepare patients for hematopoietic stem cell transplantation by suppressing bone marrow and the immune system.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
BuCy vs BuFlu TARGET	BuCy vs BuFlu	Cooperative Study Group A for Hematology	phase 3	Chemotherapy conditioning regimen
BuCy	BuCy	The First Affiliated Hospital of Soochow University	phase 3	Alkylating agent combination (chemotherapy conditioning regimen)
ASCT conditioning	ASCT conditioning	Prof. Dr. M. Dreyling (co-chairman)	phase 3	High-dose chemotherapy conditioning regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy conditioning regimen class)

Cooperative Study Group A for Hematology · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BuCy vs BuFlu — Competitive Intelligence Brief. https://druglandscape.com/ci/bucy-vs-buflu. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab